The Pacific Northwest Udall Center (PANUC) is a collaborative enterprise among physicians and scientists at Oregon Health &Science University and the University of Washington that focuses considerable experience and expertise on cognitive impairment, a relatively poorly understood but devastating consequence that is common in patients afflicted with Parkinson's disease (PD). This proposed new Udall Center would be the only one in Oregon or the WWAMl region;WWAMI is an acronym for the cooperative arrangement among states in Pacific Northwest for which the University of Washington is the only medical school and academic medical center: Washington, Wyoming, Alaska, Montana, and Idaho. Thus, PANUC would cOver an area greater than one-fourth of the entire U.S.A. where more than 13 million Americans live. PANUC will achieve several goals of the NIH and NINDS. PANUC is: eminently patient-oriented, focused on a common non-motor feature of PD that is relatively poorly understood, organized into highly inter-related cores and projects that will promote exchange of new knowledge among clinical, translational, and basic research, anxious to contribute fully to the PD Data Organizing Center (PD-DOC) and the Coriell Institute for submission to the NINDS Human Genefics Repository, and composed of investigators who have a longstanding track record of highly collaborative productivity despite being at two institutions. Our mission is twofold. First, PANUC will serve PD patients, along with their caregivers and health care providers. We will provide improved education and clinical care, as well as offer new opportunities to participate in clinical research. Second, PANUC will discover and investigate the mechanisms that underlie cognitive impairment in PD using an array of cutting-edge technologies from accomplished and collaborative laboratories, generating novel resources for the community of scientists focused on PD, and identifying potential targets for future therapeutic development.
PANUC has a three-fold mission: (i) Serve patients with Parkinson disease (PD), along with their caregivers and health care providers, (ii) Investigate and elucidate mechanisms that underlie cognitive impairment (Cl) in PD using an array of cutting-edge technologies from accomplished laboratories, identifying targets for future therapeutic development, and (iii) Create new knowledge and generate novel resources for clinical, translational, and basic research to be shared with the community of scientists investigating Cl in PD.
|Smulders, Katrijn; Dale, Marian L; Carlson-Kuhta, Patricia et al. (2016) Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism Relat Disord 31:3-13|
|Wang, Liyong; Maldonado, Lizmarie; Beecham, Gary W et al. (2016) DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet 2:e72|
|Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102|
|Mata, Ignacio F; Davis, Marie Y; Lopez, Alexis N et al. (2016) The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet 171:925-30|
|Costa-Mallen, Paola; Zabetian, Cyrus P; Hu, Shu-Ching et al. (2016) Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna) 123:1319-1330|
|Moelter, Stephen T; Weintraub, Daniel; Mace, Lauren et al. (2016) Research consent capacity varies with executive function and memory in Parkinson's disease. Mov Disord 31:414-7|
|Cholerton, Brenna; Larson, Eric B; Quinn, Joseph F et al. (2016) Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 186:500-6|
|Davis, Marie Y; Johnson, Catherine O; Leverenz, James B et al. (2016) Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol 73:1217-1224|
|Costa-Mallen, Paola; Zabetian, Cyrus P; Agarwal, Pinky et al. (2016) Response to the letter ""Haptoglobin phenotype and Parkinson disease risk"" by Delanghe et al. Parkinsonism Relat Disord 22:110-1|
|Crane, Paul K; Gibbons, Laura E; Dams-O'Connor, Kristen et al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 73:1062-9|
Showing the most recent 10 out of 151 publications